JP2016505019A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505019A5
JP2016505019A5 JP2015552887A JP2015552887A JP2016505019A5 JP 2016505019 A5 JP2016505019 A5 JP 2016505019A5 JP 2015552887 A JP2015552887 A JP 2015552887A JP 2015552887 A JP2015552887 A JP 2015552887A JP 2016505019 A5 JP2016505019 A5 JP 2016505019A5
Authority
JP
Japan
Prior art keywords
deuterium
compound according
disease
pharmaceutically acceptable
enriched compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552887A
Other languages
English (en)
Japanese (ja)
Other versions
JP6359563B2 (ja
JP2016505019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011440 external-priority patent/WO2014110558A1/en
Publication of JP2016505019A publication Critical patent/JP2016505019A/ja
Publication of JP2016505019A5 publication Critical patent/JP2016505019A5/ja
Application granted granted Critical
Publication of JP6359563B2 publication Critical patent/JP6359563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552887A 2013-01-14 2014-01-14 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 Active JP6359563B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361752055P 2013-01-14 2013-01-14
US61/752,055 2013-01-14
US201361786024P 2013-03-14 2013-03-14
US61/786,024 2013-03-14
PCT/US2014/011440 WO2014110558A1 (en) 2013-01-14 2014-01-14 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018116936A Division JP6749364B2 (ja) 2013-01-14 2018-06-20 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Publications (3)

Publication Number Publication Date
JP2016505019A JP2016505019A (ja) 2016-02-18
JP2016505019A5 true JP2016505019A5 (enExample) 2017-02-16
JP6359563B2 JP6359563B2 (ja) 2018-07-18

Family

ID=51167442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015552887A Active JP6359563B2 (ja) 2013-01-14 2014-01-14 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
JP2018116936A Active JP6749364B2 (ja) 2013-01-14 2018-06-20 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018116936A Active JP6749364B2 (ja) 2013-01-14 2018-06-20 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Country Status (6)

Country Link
US (4) US9540340B2 (enExample)
EP (1) EP2943201B2 (enExample)
JP (2) JP6359563B2 (enExample)
AU (1) AU2014205043B2 (enExample)
CA (1) CA2935495C (enExample)
WO (1) WO2014110558A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
CN106083812A (zh) 2011-03-11 2016-11-09 细胞基因公司 3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮的固体形式及其药物组合物和用途
CA2867134C (en) 2011-03-28 2019-05-07 Sheila Dewitt 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP2015531776A (ja) 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
JP6359563B2 (ja) * 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
AR096165A1 (es) * 2013-05-01 2015-12-09 Celgene Corp Síntesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin-2,6-diona
AR099385A1 (es) * 2014-01-15 2016-07-20 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
AU2016288246A1 (en) 2015-07-02 2018-02-01 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017121388A1 (zh) * 2016-01-14 2017-07-20 康朴生物医药技术（上海）有限公司 喹唑啉酮衍生物、其制备方法、药物组合物及应用
BR112019010559B1 (pt) 2016-12-16 2024-01-30 Kangpu Biopharmaceuticals, Ltd Combinação, seu uso, composição farmacêutica, e kit
KR102014478B1 (ko) * 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
US11773080B2 (en) 2017-12-22 2023-10-03 Salarius Pharmaceuticals, Inc. Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same
WO2021168314A1 (en) * 2020-02-21 2021-08-26 Plexium, Inc. Quinazolinone compounds and related compounds
EP4185380A4 (en) * 2020-07-24 2024-08-21 Inipharm, Inc. Quinazolinone hsd17b13 inhibitors and uses thereof
TWI893238B (zh) 2020-11-13 2025-08-11 美商伊尼製藥股份有限公司 二氯酚hsd17b13抑制劑及其用途
WO2024108028A1 (en) 2022-11-16 2024-05-23 Salarius Pharmaceuticals, Inc. Methods of use of deuterium-enriched compounds
AU2024206378A1 (en) * 2023-01-06 2025-07-10 Salarius Pharmaceuticals, Inc Solid forms and methods of use
WO2024220489A1 (en) 2023-04-18 2024-10-24 Salarius Pharmaceuticals, Inc. Deuterium-enriched compound for use in a method of treatment of multiple myeloma

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4421865A (en) 1981-06-08 1983-12-20 Standard Oil Company (Sohio) Selective hydrogen-deuterium interchange using ion exchange resins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5149820A (en) 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
KR20050032629A (ko) 1996-07-24 2005-04-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-프탈이미드와 치환된2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린과 ＴＮＦα농도를 감소시키는 방법
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
KR20060036124A (ko) 1998-03-16 2006-04-27 셀진 코포레이션 염증성 사이토카인 억제제용2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그제조방법 및 그 용도
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CN1511420A (zh) 2001-11-09 2004-07-07 ���µ�����ҵ��ʽ���� 运动图像编码方法和装置
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1694328A4 (en) 2003-12-02 2010-02-17 Celgene Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
MXPA06010699A (es) 2004-03-22 2006-12-15 Celgene Corp Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20080199422A1 (en) 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
MXPA06012278A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
WO2006053160A2 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
CN101102771A (zh) 2004-11-23 2008-01-09 细胞基因公司 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
WO2006060507A2 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
US20060270707A1 (en) 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
DK2380887T3 (da) 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
JP5578785B2 (ja) 2005-08-31 2014-08-27 セルジーン コーポレイション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
JP2009507030A (ja) 2005-09-01 2009-02-19 セルジーン・コーポレーション ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20080064876A1 (en) 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
WO2008027542A2 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CL2007002670A1 (es) 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
AR065810A1 (es) 2007-03-20 2009-07-01 Celgene Corp Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
US20090022706A1 (en) 2007-07-20 2009-01-22 Auspex Pharmaceuticals, Inc. Substituted cyclohexenes
KR100879636B1 (ko) 2007-08-22 2009-01-21 한국과학기술연구원 세로토닌 ５―ｈｔ₃ａ 길항적 효과를 갖는 퀴나졸린유도체 함유 약제 조성물
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
US8354417B2 (en) 2007-09-26 2013-01-15 Celgene Corporation Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
UA102078C2 (ru) 2007-09-26 2013-06-10 Селджин Корпорэйшн 6-, 7- или 8-замещенные производные хиназолинона и композиция, которая их содержит, и способ их использования
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
EP2235213A2 (en) 2007-12-20 2010-10-06 Celgene Corporation Use of micro-rna as a biomarker of immunomodulatory drug activity
CN101977603A (zh) 2008-01-29 2011-02-16 细胞基因公司 使用免疫调节化合物来调节cd59水平的方法
WO2009105256A2 (en) 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
WO2009139880A1 (en) 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
MX361467B (es) 2008-10-29 2018-12-06 Celgene Corp Compuestos de isoindolina para uso en el tratamiento de cancer.
KR101649332B1 (ko) 2008-11-14 2016-08-18 콘서트 파마슈티컬즈, 인크. 치환된 다이옥소피페리디닐 프탈이미드 유도체
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US8716314B2 (en) 2009-02-11 2014-05-06 Celgene Corporation Isotopologues of thalidomide
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
US20120322799A1 (en) 2009-11-30 2012-12-20 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
SI2536706T1 (sl) 2010-02-11 2017-10-30 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2012229300B2 (en) 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
CN106083812A (zh) * 2011-03-11 2016-11-09 细胞基因公司 3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮的固体形式及其药物组合物和用途
CA2867134C (en) 2011-03-28 2019-05-07 Sheila Dewitt 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP3096142A3 (en) 2011-04-29 2017-03-08 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
AU2013299625B2 (en) 2012-08-09 2018-02-01 Celgene Corporation Treatment of immune-related and inflammatory diseases
MX2015001633A (es) 2012-08-09 2015-04-08 Celgene Corp Procesos para la preparacion de (s)-3-4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2,6-diona y formas farmaceuticamente aceptables de la misma.
EP3950681A3 (en) 2012-08-09 2022-04-13 Celgene Corporation Salts and solid forms of the compound (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
JP2015531776A (ja) * 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
WO2014039960A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
JP6359563B2 (ja) * 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES

Similar Documents

Publication Publication Date Title
JP2016505019A5 (enExample)
JP2016508505A5 (enExample)
RU2018126793A (ru) Тетрагидропиранил амино-пирролопиримидинон и способы его применения
RU2013156687A (ru) Антагонисты рецептора св1
JP2018518537A5 (enExample)
JP2015502979A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2016506916A5 (enExample)
RU2015137757A (ru) Производные пиридазинон-амидов
JP2016532657A5 (enExample)
HRP20191430T1 (hr) Spojevi heteroarila kao inhibitori btk i njihove uporabe
JP2015511609A5 (enExample)
JP2018537535A5 (enExample)
JP2019529444A5 (enExample)
RU2013144579A (ru) Ингибиторы киназы mst1 и способы их применения
CN108601952B (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
JP2017514910A5 (enExample)
JP2018536628A5 (enExample)
JP2019535723A5 (enExample)
JP2021501151A5 (enExample)
JP2019504087A5 (enExample)
JP2017511321A5 (enExample)
JP2013507371A5 (enExample)
JP2012532883A5 (enExample)
JP2013507374A5 (enExample)